Prospective Study of White Blood Cells
Recruiting
- Conditions
- Autoimmune DiseasesInflammationRejection; Transplant, Liver
- Registration Number
- NCT04838171
- Lead Sponsor
- Quell Therapeutics Limited
- Brief Summary
The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method WBC characterisation to support the development of engineered regulatory T cells. 5 years number, type and function of white blood cells in healthy controls and in patients
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie engineered Treg therapy in autoimmune diseases and liver transplant rejection?
How effective are engineered Treg therapies compared to standard-of-care immunosuppressants in preventing transplant rejection?
Which biomarkers are used to select patients for Treg-based therapies in autoimmune and inflammatory conditions?
What adverse events are associated with Treg cell engineering and how are they managed in clinical trials?
Are there combination approaches involving Treg therapies with other immunomodulators for treating autoimmune diseases?
Trial Locations
- Locations (1)
Quell Investigator Site 01
🇬🇧London, United Kingdom
Quell Investigator Site 01🇬🇧London, United Kingdom